Literature DB >> 10823844

Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes.

H Ruppach1, P Nara, I Raudonat, Z Elanjikal, H Rübsamen-Waigmann, U Dietrich.   

Abstract

The aim of this study was to analyze the role of humoral immunity in early human immunodeficiency virus (HIV) infection. As neutralizing activities in HIV-positive sera are rarely detectable earlier than 9 to 12 months after infection using primary lymphocytes as target cells in neutralization assays, humoral immunity is generally thought not to contribute significantly to early virus control in the patients. Besides lymphocytes, cells of the monocyte/macrophage lineage are known to be important target cells for HIV in vivo during the establishment of the infection. Therefore, we studied the neutralization of early primary HIV isolates by autologous serum samples using primary macrophages as target cells in the neutralization assays. We analyzed neutralizing activities against the autologous HIV-1 isolates in 10 patients' sera taken shortly after seroconversion, both on primary macrophages and, for comparison, on lymphocytes. Viruses were isolated and expanded in primary mixed cultures containing macrophages and lymphocytes in order to avoid selection for one particular cell type. All viruses replicated to different degrees in macrophages and lymphocytes; nine had a nonsyncytium-inducing phenotype, and one was syncytium inducing. The detection of neutralizing antibodies in acute primary HIV infection depended on the target cells used. Confirming previous studies, we did not find neutralizing activities on lymphocytes at this early time point. In contrast, neutralizing activities were detectable in the same sera if primary macrophages were used as target cells. Differences in neutralizing activities on macrophages and lymphocytes were not due to different virus variants being present in the different cell systems, as gp120 sequences derived from both cell types were homogeneous. Neutralization activities on macrophages did not correlate with the amount of beta-chemokines in the sera. As affinity-purified immunoglobulin G preparations from an early patient serum also exhibited neutralization of the autologous virus isolate on primary macrophages, but not on lymphocytes, neutralization is very likely due to antibodies against viral epitopes necessary for infection of macrophages but not for infection of lymphocytes. Our data suggest that, along with cell-mediated immunity, humoral immunity may contribute to the reduction of primary viremia in the patient. This was further supported by a certain association between neutralizing antibody titers on macrophages and viral load in the patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10823844      PMCID: PMC112024          DOI: 10.1128/jvi.74.12.5403-5411.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  57 in total

Review 1.  Neutralization of HIV-1 by antibody.

Authors:  Q J Sattentau
Journal:  Curr Opin Immunol       Date:  1996-08       Impact factor: 7.486

2.  The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates.

Authors:  H Choe; M Farzan; Y Sun; N Sullivan; B Rollins; P D Ponath; L Wu; C R Mackay; G LaRosa; W Newman; N Gerard; C Gerard; J Sodroski
Journal:  Cell       Date:  1996-06-28       Impact factor: 41.582

3.  Standard conditions of virus isolation reveal biological variability of HIV type 1 in different regions of the world. WHO Network for HIV Isolation and Characterization.

Authors:  H Rübsamen-Waigmann; H von Briesen; H Holmes; A Björndal; B Korber; R Esser; S Ranjbar; P Tomlinson; B Galvao-Castro; E Karita
Journal:  AIDS Res Hum Retroviruses       Date:  1994-11       Impact factor: 2.205

4.  A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors.

Authors:  B J Doranz; J Rucker; Y Yi; R J Smyth; M Samson; S C Peiper; M Parmentier; R G Collman; R W Doms
Journal:  Cell       Date:  1996-06-28       Impact factor: 41.582

5.  Altered cytokine production and accessory cell function after HIV-1 infection.

Authors:  J Yoo; H Chen; T Kraus; D Hirsch; S Polyak; I George; K Sperber
Journal:  J Immunol       Date:  1996-08-01       Impact factor: 5.422

6.  Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells.

Authors:  F Cocchi; A L DeVico; A Garzino-Demo; S K Arya; R C Gallo; P Lusso
Journal:  Science       Date:  1995-12-15       Impact factor: 47.728

7.  Mechanisms of HIV/SIV mucosal transmission.

Authors:  G Milman; O Sharma
Journal:  AIDS Res Hum Retroviruses       Date:  1994-10       Impact factor: 2.205

8.  Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.

Authors:  J W Mellors; C R Rinaldo; P Gupta; R M White; J A Todd; L A Kingsley
Journal:  Science       Date:  1996-05-24       Impact factor: 47.728

9.  Conserved V3 loop sequences and transmission of human immunodeficiency virus type 1.

Authors:  E G Shpaer; E L Delwart; C L Kuiken; J Goudsmit; M H Bachmann; J I Mullins
Journal:  AIDS Res Hum Retroviruses       Date:  1994-12       Impact factor: 2.205

10.  Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection.

Authors:  S M Wolinsky; B T Korber; A U Neumann; M Daniels; K J Kunstman; A J Whetsell; M R Furtado; Y Cao; D D Ho; J T Safrit
Journal:  Science       Date:  1996-04-26       Impact factor: 47.728

View more
  8 in total

1.  During readaptation in vivo, a tissue culture-adapted strain of feline immunodeficiency virus reverts to broad neutralization resistance at different times in individual hosts but through changes at the same position of the surface glycoprotein.

Authors:  M Bendinelli; M Pistello; D Del Mauro; G Cammarota; F Maggi; A Leonildi; S Giannecchini; C Bergamini; D Matteucci
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity.

Authors:  Manish Sagar; Xueling Wu; Sandra Lee; Julie Overbaugh
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

3.  Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells.

Authors:  D N Forthal; G Landucci; E S Daar
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.

Authors:  Ming Li; Feng Gao; John R Mascola; Leonidas Stamatatos; Victoria R Polonis; Marguerite Koutsoukos; Gerald Voss; Paul Goepfert; Peter Gilbert; Kelli M Greene; Miroslawa Bilska; Denise L Kothe; Jesus F Salazar-Gonzalez; Xiping Wei; Julie M Decker; Beatrice H Hahn; David C Montefiori
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

5.  Neutralizing antibody responses in recent seroconverters with HIV-1 subtype C infections in India.

Authors:  Smita Kulkarni; Srikanth Tripathy; Raman Gangakhedkar; Sushama Jadhav; Kalpana Agnihotri; Suvarna Sane; Robert Bollinger; Ramesh Paranjape
Journal:  AIDS Res Hum Retroviruses       Date:  2008-09       Impact factor: 2.205

6.  Antibody-Mediated Fcγ Receptor-Based Mechanisms of HIV Inhibition: Recent Findings and New Vaccination Strategies.

Authors:  Vincent Holl; Maryse Peressin; Christiane Moog
Journal:  Viruses       Date:  2009-12-15       Impact factor: 5.048

7.  Neutralizing Antibodies Against a Specific Human Immunodeficiency Virus gp41 Epitope are Associated With Long-term Non-progressor Status.

Authors:  Olivier Lucar; Bin Su; Valérie Potard; Assia Samri; Brigitte Autran; Christiane Moog; Patrice Debré; Vincent Vieillard
Journal:  EBioMedicine       Date:  2017-07-11       Impact factor: 8.143

8.  Neutralization and beyond: Antibodies and HIV-1 acquisition.

Authors:  Allison S Thomas; Melissa Ghulam-Smith; Manish Sagar
Journal:  Curr Top Virol       Date:  2018
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.